Michelle Vaughan

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Jonathan A. Ledermann, Andrew Embleton-Thirsk, Fharat Raja et al. · The Lancet · 2016 · 239 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

JA Ledermann, Timothy Perren, FA Raja et al. · UCL Discovery (University College London) · 2013 · 102 citations

Medicine, Gynecology, Oncology +17

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Florence Joly, Isabelle Ray‐Coquard, Michel Fabbro et al. · Gynecologic Oncology · 2011 · 71 citations

Medicine, Oncology, Pharmacology +17

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

Jonathan A. Ledermann, Andrew Embleton-Thirsk, Timothy Perren et al. · ESMO Open · 2021 · 29 citations · Full text

Medicine, Oncology, Pharmacology +16

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study

Prunella Blinman, Corona Gainford, Mark W. Donoghoe et al. · Journal of Gynecologic Oncology · 2013 · 21 citations · Full text

Medicine, Oncology, Surgery +16